Photo: Repina Valeriya / Shutterstock.com
12 March 2014Americas
Myriad suffers setback in attempt to block Ambry BRCA test
Genetic diagnostic company Myriad Genetics and other patent holders have been denied a motion for a preliminary injunction that would have kept rival company Ambry Genetics from selling its own test for the BRCA gene mutations that put women at risk of developing breast and ovarian cancer.
